0001683168-26-003822
SEC filingQ1 revenue grew 11.3% to $21.1K from UK NOCISCAN® sales momentum, achieving positive gross profit of $3.8K versus prior loss, though operating loss widened to -$3.0M on commercialization investments.
Revenue increased 11.3% to $21,140 in Q1 FY2026 from $18,991 in the prior-year period, driven primarily by the growing volume of NOCISCAN® reports sold into the UK market following recent local coverage decisions. This reflects early commercial validation of Aclarion's healthcare technology platform utilizing MRS biomarkers, as international traction broadens the addressable market beyond prior US-focused, non-reimbursed sales. Management views this as a foundation for continued topline expansion as additional payors adopt coverage, though absolute scale remains modest at this pre-scale commercialization stage.
Gross profit swung to a positive $3.8K (17.7% margin) from a -$4.5K loss in Q1 FY2025, representing a 183.6% improvement. This inflection resulted primarily from a reduced allocation of hosting fees to cost of revenue and a change in revenue mix that lowered partner fees. The positive gross profit demonstrates improving unit economics and cost discipline, enabling better coverage of direct expenses as UK sales volume ramps. This positions the business to scale margins with revenue growth, assuming sustained coverage momentum and stable cost structures.
Net cash provided by operating activities was -$2.6M, similar to -$2.5M last year. Changes in working capital partially offset the increase in cash used for operations. Management believes current cash resources suffice to fund operating expenses and capital needs for at least twelve months from issuance and into H2 2027, providing runway for ongoing development despite expected future increases in cash burn as business advances.